A Libtayo combo fails to beat Keytruda in first-line melanoma.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
But PFS data are lacking, and there are questions about first and second-line plans.
But the company still has a lot to prove with ERAS-0015.
Three private biotechs enter clinical trials, one targeting KRAS.
